Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3
The experimentally established mechanism targets of Dipivefrin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 5/20 | 0.97 |
| ▸ | ADRB1 known ✓ | P08588 | 3/20 | 0.48 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.48 |
| ▸ | ADRB3 known ✓ | P13945 | 3/20 | 0.48 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 0.48 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 0.48 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.48 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 0.48 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dipivefrin SCHEMBL29710905 | 1.00 | HIF1A (1.00) | HIF1AALDH1A1CYP3A4LMNAADRB2 | |
| Dipivefrin SCHEMBL24714 | 1.00 | HIF1A (1.00) | HIF1AALDH1A1CYP3A4LMNAADRB2 | |
| Dipivefrin SCHEMBL20673238 | 1.00 | HIF1A (1.00) | HIF1AALDH1A1CYP3A4LMNAADRB2 | |
| Dipivefrin SCHEMBL41351 | 0.99 | ADRB2 (1.00) | HIF1AALDH1A1CYP3A4LMNAADRB2 | |
| Dipivefrin SCHEMBL41350 | 0.99 | ADRB2 (1.00) | HIF1AALDH1A1CYP3A4LMNAADRB2 | |
| Dipivefrin SCHEMBL18687014 | 0.99 | ADRB2 (1.00) | HIF1AALDH1A1CYP3A4LMNAADRB2 | |
| Dipivefrin SCHEMBL5275338 | 0.99 | ADRB2 (1.00) | HIF1AALDH1A1CYP3A4LMNAADRB2 | |
| Dipivefrin SCHEMBL8071336 | 0.99 | ADRB2 (1.00) | HIF1AALDH1A1CYP3A4LMNAADRB2 | |
| Dipivefrin SCHEMBL3053588 | 0.97 | HIF1A (0.95) | HIF1AALDH1A1CYP3A4LMNAADRB2 | |
| Dipivefrin SCHEMBL6422300 | 0.93 | HIF1A (0.86) | HIF1AALDH1A1CYP3A4LMNAADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5668 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724079-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4710918-A1 | OPHTHALMIC PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR, OPHTHALMIC KIT CONTAINING OPHTHALMIC PHARMACEUTICAL COMPOSITION, AND USE | Shenyang Xingqi Pharmaceutical Co., Ltd. (CN) | 2026-03-18 | — | — | EP | claimed |
| EP-4704839-A2 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | ALPHERABIO LLC (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260048096-A1 | METHODS AND COMPOSITIONS FOR PRESERVING THE RETINAL OUTER NUCLEAR LAYER (ONL), PHOTORECEPTORS, AND RETINAL THICKNESS | STEALTH BIOTHERAPEUTICS INC. (US) | 2026-02-19 | — | — | US | claimed |
| US-20250339378-A1 | THERMORESPONSIVE HYDROGEL CONTAINING POLYMER MICROPARTICLES FOR NONINVASIVE OCULAR DRUG DELIVERY | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2025-11-06 | — | — | US | claimed |
| US-12433850-B2 | Enhanced delivery epinephrine and prodrug compositions | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-10-07 | — | — | US | claimed |
| US-12427121-B2 | Enhanced delivery epinephrine compositions | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-09-30 | — | — | US | claimed |
| US-20250281407-A1 | LIPID DEPOT FORMULATIONS | CAMURUS AB (SE) | 2025-09-11 | — | — | US | claimed |
| US-12396959-B2 | Thermoresponsive hydrogel containing polymer microparticles for noninvasive ocular drug delivery | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-08-26 | — | — | US | claimed |
| EP-4596049-A2 | PEPTIDE FOR USE IN PREVENTING OR TREATING MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2025-08-06 | — | — | EP | claimed |
| WO-1991016869-A1 | POLYMERIC DRUG DELIVERY SYSTEM | ALLERGAN, INC. (US) | 1991-11-14 | — | — | WO | claimed |
| US-5055467-A | Chemical intermediates to antiglaucoma agents | ALLERGAN, INC. (US) | 1991-10-08 | — | — | US | claimed |
| EP-0126684-B1 | DRUG DELIVERY SYSTEM UTILIZING THERMOSETTING GELS | MERCK & CO. INC. (US) | 1991-08-28 | — | — | EP | claimed |
| EP-0432899-A1 | Novel pharmaceutical epinephrine-pilocarpine derivatives | ALLERGAN, INC. (US) | 1991-06-19 | — | — | EP | claimed |
| US-4904649-A | CORTICOSTEROIDS AND BETA ADRENERGIC AGENTS | NEW ENGLAND MEDICAL CENTER HOSPITALS, INC. (US) | 1990-02-27 | — | — | US | claimed |
| WO-1987007141-A1 | METHOD FOR TREATING GLAUCOMA | NEW ENGLAND MEDICAL CENTER HOSPITALS, INC. (US) | 1987-12-03 | — | — | WO | claimed |
| EP-0126684-A2 | Drug delivery system utilizing thermosetting gels | MERCK & CO. INC. (US) | 1984-11-28 | — | — | EP | claimed |
| US-4474751-A | SUSTAINED RELEASE USING AN ALKYLENEDIAMINE-MODIFIED ETHYLENE OXIDE-PROPYLENE OXIDE COPOLYMER | MERCK & CO., INC. (US) | 1984-10-02 | — | — | US | claimed |
| EP-0047339-A1 | Drug for the local treatment of glaucoma | Dr. Thilo & Co. GmbH (DE) | 1982-03-17 | — | — | EP | claimed |
| US-4145441-A | SYMPATHOMIMETIC AMINES EXHIBITING ANTI-HEMORRHOIDAL ACTIVITY | INTERX RESEARCH CORPORATION (US) | 1979-03-20 | — | — | US | claimed |